文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

休克状态下血管加压素的使用:欧洲重症医学会支持的国际调查PRESS研究

Vasopressin use across shock states: international insights from an international ESICM-endorsed survey: the PRESS Survey.
PubMed 文献 · Crit Care · 2025-07-03
一句话结论国际调查显示血管加压素/特利加压素广泛用于脓毒性休克二线升压,但起始剂量与撤药实践差异大,需规范指导。

该研究为欧洲重症医学会支持的国际调查,评估血管加压素和特利加压素在脓毒性休克中的使用现状。共1919名来自124个国家的重症医生回复,95%的受访者所在科室备有血管加压素或特利加压素,78%的受访者使用该药,其中93%作为初始复苏后的二线升压药,主要用于升高血压和减少儿茶酚胺负荷。去甲肾上腺素剂量或用药时长单独触发起始的比例分别为98%和53%,最常用的去甲肾上腺素碱剂量为0.25-0.50 µg/kg/min,最常见时长为>2-6小时。起始剂量0.01或0.03 U/min各占50%,撤药实践异质性大。结论认为血管加压素常用于脓毒性休克,但剂量和撤药实践仍不统一,提示需要临床使用指导。

要点

  • 78%的受访者使用血管加压素或特利加压素,其中93%作为初始复苏后的二线升压药,主要用于升高血压和减少儿茶酚胺负荷。
  • 去甲肾上腺素碱剂量0.25-0.50 µg/kg/min是最常见的起始触发剂量,>2-6小时是最常见的触发时长。
  • 血管加压素起始剂量0.01或0.03 U/min各被50%的受访者使用。
  • 88%的受访者以平均动脉压水平触发血管加压素或特利加压素减量,89%的受访者撤药过程为渐进性。
  • 主要报告的禁忌证为非闭塞性肠系膜缺血和指端或皮肤缺血。

适用人群与场景

  • 脓毒性休克患者,作为初始复苏后的二线升压药使用(93%的受访者)。
  • 难治性脓毒性休克、各类难治性休克中减少儿茶酚胺负荷、非脓毒性难治性血管麻痹性休克且左室收缩功能未降低、高心输出量低体循环血管阻力的脓毒性休克为报告的主要适应证。

诊断标准与关键阈值

  • 去甲肾上腺素碱剂量0.25-0.50 µg/kg/min是最常见的起始触发剂量。
  • 去甲肾上腺素用药时长>2-6小时是最常见的起始触发时长。
  • 去甲肾上腺素碱剂量>0.25或>0.50 µg/kg/min持续>2-6小时是最常见的剂量联合时长触发组合,78%的受访者采用剂量联合时长触发。

处置流程与药物剂量

  • 血管加压素或特利加压素作为初始复苏后的二线升压药,用于升高血压和减少儿茶酚胺负荷(93%的受访者)。
  • 血管加压素起始剂量0.01或0.03 U/min各被50%的受访者使用。
  • 88%的受访者以平均动脉压水平触发血管加压素或特利加压素减量。
  • 43%的受访者在第一线升压药剂量降至预设阈值以下后开始停用血管加压素或特利加压素,89%的受访者撤药过程为渐进性。

红旗征与不能漏的情况

  • 非闭塞性肠系膜缺血为主要报告的禁忌证。
  • 指端或皮肤缺血为主要报告的禁忌证。

研究设计与关键结果

  • 研究类型为欧洲重症医学会支持的国际调查,共1919名来自124个国家的重症医生回复。
  • 1220名(64%)受访者在欧洲工作,1430名(74%)在高收入和中高收入国家工作,916名(48%)在学术型ICU工作。
  • 1830名(95%)受访者所在科室备有血管加压素或特利加压素。
  • 主要适应证为难治性脓毒性休克(73%)、各类难治性休克中减少儿茶酚胺负荷(53%)、非脓毒性难治性血管麻痹性休克且左室收缩功能未降低(51%)、高心输出量低体循环血管阻力的脓毒性休克(49%)。
  • 1506名(78%)受访者使用血管加压素或特利加压素,其中93%作为初始复苏后的二线升压药。
  • 98%的受访者以去甲肾上腺素剂量单独触发起始,53%以去甲肾上腺素用药时长单独触发起始。

证据类型、等级与局限

  • 证据类型为国际调查(欧洲重症医学会支持)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 调查显示血管加压素/特利加压素在脓毒性休克中作为二线升压药广泛使用,但起始剂量(0.01或0.03 U/min各半)和撤药实践异质性大,提示需要临床使用指导。

指南或共识出处

  • 欧洲重症医学会(European Society of the Intensive Care Medicine)支持的PRESS调查

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Vasopressin is currently suggested as a second-line vasopressor in patients with septic shock and persistent arterial hypotension. This survey aimed to assess the current use of vasopressin and terlipressin in patients with septic shock.

METHODS: An international survey endorsed by the European Society of the Intensive Care Medicine. All items addressed the different areas of uncertainty and research identified from current international recommendations. RESULTS: 1919 intensivists from 124 countries responded to the survey: 1220(64%) worked in Europe, 1430(74%) in high and upper-middle income level countries and 916(48%) in academic ICUs. Vasopressin or terlipressin were available to 1830(95%) respondents. The main reported indications were refractory septic shock, catecholamine sparing in all types of refractory shock, refractory vasoplegic shock (other than septic) without reduced left ventricular systolic function and septic shock with high cardiac output and low systemic vascular resistance (73%,53%,51% and 49% of respondents, respectively). The main reported contraindications were non-occlusive mesenteric ischemia and digital or skin ischemia. Overall, 1506(78%) respondents used vasopressin or terlipressin, 93% of them as a second-line vasopressor after initial resuscitation, mainly to increase blood pressure and reduce the catecholamine load. The dose of norepinephrine alone or the duration of norepinephrine administration alone triggered vasopressin and terlipressin initiation for 98% and 53% of respondents, respectively: the most frequent dose of norepinephrine base was 0.25-0.50 µg/kg/min and the most frequent duration was > 2-6 h. The combination of the dose of norepinephrine base and the duration of its administration triggered vasopressin and terlipressin initiation for 78% of respondents, the most frequent combination being a norepinephrine base dose > 0.25 or > 0.50 µg/kg/min for > 2-6 h. An initial dose of vasopressin of 0.01 or 0.03 U/min was used by 50% of respondents. The mean arterial pressure level triggered the tapering of vasopressin or terlipressin for 88% of respondents. Discontinuation started after the dose of the first-line vasopressor had been lowered below a predefined threshold for 43% of respondents and was progressive for 89% of respondents.

CONCLUSIONS: Vasopressin is commonly used to treat patients with septic shock, but its handling (doses and discontinuation practices) remains heterogeneous, indicating the need for guidance in its clinical use.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Jozwiak M, Cousin VL, De Backer D, et al. Vasopressin use across shock states: international insights from an international ESICM-endorsed survey: the PRESS Survey. Crit Care. 2025. PMID: 40611266. doi:10.1186/s13054-025-05505-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。